نتائج البحث - Jan Buter

  • يعرض 1 - 15 نتائج من 15
تنقيح النتائج
  1. 1
    Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients

    Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients حسب Judith Nieken, NH Mulder, Jan Buter, Edo Vellenga, P. C. Limburg, D. A. Piers, Elisabeth G.E. de Vries

    منشور في 1995
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

    A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus حسب Bernard M. Tijink, Jan Buter, Remco de Bree, Giuseppe Giaccone, Margreet Lang, Alexander Staab, C. René Leemans, Guus A.M.S. van Dongen

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2

    Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2 حسب B. J. Kroesen, Jan Buter, D.Th. Sleijfer, René A. J. Janssen, Wta van der Graaf, TH The, L de Leij, NH Mulder

    منشور في 1994
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings

    Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings حسب Karen Hilverda, Ingeborg Bosma, J.J. Heimans, Tjeerd J. Postma, W. Peter Vandertop, Ben J. Slotman, Jan Buter, Jaap C. Reijneveld, Martin Klein

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma

    Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma حسب Chris Nutting, Carla M.L. van Herpen, Aisha Miah, Shree Bhide, J.-P. Machiels, Jan Buter, C. Kelly, Dominique de Raucourt, Kevin J. Harrington

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI

    Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL a... حسب Rico N. P. M. Rinkel, Irma M. Verdonck‐de Leeuw, P. Doornaert, Jan Buter, Remco de Bree, Johannes A. Langendijk, Neil K. Aaronson, C. René Leemans

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies

    Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies حسب H.T. Mouridsen, Seppo W. Langer, Jan Buter, Holger Eidtmann, Giovanni Rosti, Maike de Wit, Poul Knoblauch, Asenath Rasmussen, K K Dahlstrøm, Peter Bjødstrup Jensen, Giuseppe Giaccone

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

    Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial حسب C. Rasch, Michael Hauptmann, Jan H. Schornagel, Oda B. Wijers, Jan Buter, Theo Gregor, Ruud Wiggenraad, Jan Paul de Boer, Annemiek H. Ackerstaff, Robert Kröger, Frank Hoebers, Alfons J. M. Balm

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    The course of symptoms of anxiety and depression from time of diagnosis up to 2 years follow-up in head and neck cancer patients treated with primary (chemo)radiation

    The course of symptoms of anxiety and depression from time of diagnosis up to 2 years follow-up in head and neck cancer patients treated with primary (chemo)radiation حسب Florie E. van Beek, Femke Jansen, Lisa Yuen Hong Mak, Birgit I. Lissenberg‐Witte, Jan Buter, Marije R. Vergeer, Jens Voortman, Pim Cuijpers, C. René Leemans, Irma M. Verdonck‐de Leeuw

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program

    Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week... حسب Ingrid Cnossen, Cornelia F. van Uden–Kraan, Birgit I. Lissenberg‐Witte, Yke J. Aalders, Cees J. T. de Goede, Remco de Bree, P. Doornaert, D. Rietveld, Jan Buter, Johannes A. Langendijk, C. René Leemans, Irma M. Verdonck‐de Leeuw

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial حسب Renske Gahrmann, Martin J. van den Bent, Bronno van der Holt, René M. Vernhout, Walter Taal, Maaike J. Vos, Jan Cees de Groot, Laurens V. Beerepoot, Jan Buter, Zwenneke Flach, Monique C.J. Hanse, Bas Jasperse, Marion Smits

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

    Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands حسب Eline Boon, Wim van Boxtel, Jan Buter, Robert J. Baatenburg de Jong, Robert J.J. van Es, Miranda Bel, E. Fiets, Sjoukje F. Oosting, Marije Slingerland, Ann Hoeben, Margot Tesselaar, Marianne A. Jonker, Uta Flucke, Winette T.A. van der Graaf, Carla M.L. van Herpen

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

    Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults حسب Eline Boon, Winette T.A. van der Graaf, Hans Gelderblom, Margot Tesselaar, Robert J.J. van Es, Sjoukje F. Oosting, Remco de Bree, Esther van Meerten, Ann Hoeben, Ludi E. Smeele, Stefan M. Willems, Max J. H. Witjes, Jan Buter, Robert J. Baatenburg de Jong, Uta Flucke, Petronella G.M. Peer, Judith V.M.G. Bovée, Carla M.L. van Herpen

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

    Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial حسب Lale Erdem‐Eraslan, Martin J. van den Bent, Youri Hoogstrate, Hina Naz-Khan, Andrew Stubbs, Peter J. van der Spek, René Böttcher, Ya Gao, Maurice de Wit, Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, Laurens V. Beerepoot, Monique C.J. Hanse, Jan Buter, Aafke H. Honkoop, Bronno van der Holt, René M. Vernhout, Peter A.E. Sillevis Smitt, Johan M. Kros, Pim J. French

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

    Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial حسب Hisham Mehanna, Max Robinson, A. Hartley, Anthony Kong, Bernadette Foran, Tessa Fulton‐Lieuw, Matthew J. Dalby, Pankaj Mistry, Mehmet Şen, L. O’Toole, H. Al Booz, K. Dyker, R. Molerón, S. Whitaker, Sínead Brennan, Audrey Cook, Matthew Griffin, E. Aynsley, Martin Rolles, Emma De Winton, Andrew K. Chan, Devraj Srinivasan, Ioanna Nixon, Joanne Grumett, C. René Leemans, Jan Buter, Julia Henderson, Kevin J. Harrington, Christopher C. McConkey, Alastair Gray, Janet Dunn, R. Molerón, Orla McArdle, K. Dyker, H. Al Booz, L. O’Toole, Audrey Cook, David Husband, Vivienne Loo, Win Soe, E. Aynsley, Sridhar Thiagarajan, Petra Jankowska, Mano Joseph, K. Geropantas, Deepali Vaidya, Matthew Griffin, A. Hartley, Rengarajan Vijayan, David Hwang, Kevin J. Harrington, Laura Pettit, S. Whitaker, Emma De Winton, Martin Rolles, Sínead Brennan, Mehmet Şen, R. Mendes, Martin Förster, Andrew K. Chan, Mererid Evans, Jan Buter, Devraj Srinivasan, B. Foran, Paul Nankivell, Jennifer Bryant, Neil Sharma, Rachel Spruce, Jill Brooks, Nikolaos Batis, Tom Roques, Margaret Bidmead, Huiqi Yang, Christopher M. Nutting, Justine Tyler, Julia Henderson, Helen Baines, Anne Gasnier, Elizabeth Miles, Catharine H. Clark, Mererid Evans

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: